Charles Kim serves as Executive Vice President and Chief Legal Officer of NantWorks, LLC, which he joined in 2011. In this capacity, he also serves as General Counsel for NantWorks’ portfolio companies, including NantHealth and NantKwest. In these roles, he leads the company’s legal department and is responsible for a broad range of legal areas for both the company and its portfolio companies, including general corporate matters, mergers and acquisitions, licensing, intellectual property and litigation. As the chief legal officer, Mr. Kim also functions as the company’s chief compliance officer, overseeing the company’s corporate compliance program to promote ethical business conduct throughout the organization.
Prior to NantWorks, Mr. Kim served as Senior Vice President and General Counsel of Abraxis BioScience, a publicly traded biotechnology company that he joined in September 2006. While at Abraxis BioScience, he spearheaded the separation of Abraxis BioScience and APP Pharmaceuticals in November 2007, was instrumental in the subsequent sale of APP Pharmaceuticals to Fresenius in September 2008 and orchestrated the subsequent sale of Abraxis BioScience to Celgene Corporation in October 2010. During his tenure at Abraxis BioScience and APP Pharmaceuticals, Mr. Kim was involved in all aspects of business development activities, was responsible for SEC reporting and corporate governance and provided general corporate and transactional support, including participation in board meetings and overseeing litigation and other regulatory compliance. Prior to Abraxis BioScience, Mr. Kim was a member of the corporate department at the international law firm of Morrison & Foerster LLP, where he maintained a general corporate and securities practice. Mr. Kim earned his J.D. from Loyola Law School of Los Angeles and his B.A. in Economics from the University of California at Berkeley.